Incidence of heart failure and mortality after acute coronary syndromes.Am Heart J. 2013;165:379 85. 287. Rossignol P, Menard J, Fay R, et al. Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. J Am Coll Cardiol. 2011;58:1958 66. 288. Baigent C, Blackwell L, Collins R, et al.Aspirin in the primary and second- ary prevention of vascular disease: collaborative meta-analysis of individ- ual participant data from randomised trials. Lancet. 2009;373:1849 60. 289. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494 502. 290. Mahaffey KW, Wojdyla DM, Carroll K, et al. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011;124:544 54. 291. CAPRIE Steering Committee. A randomised, blinded, trial of clopido- grel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329 39. 292. Mehta SR, Bassand JP, Chrolavicius S, et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010;363:930 42. 293. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045 57. 294. James SK, Roe MT, Cannon CP, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive man- agement: substudy from prospective randomised PLATelet inhibition and patient Outcomes (PLATO) trial. BMJ. 2011;342:d3527. 295. Giugliano RP, White JA, Bode C, et al. Early versus delayed, provisional eptifibatideinacutecoronarysyndromes.NEnglJMed.2009;360:2176 90. 296. Mehta SR, Yusuf S, Peters RJ, et al. 